Tirzepatide

Tirzepatide: A dual GIP and GLP-1 receptor agonist studied in metabolic regulation.

What is it?

A dual GIP and GLP-1 receptor agonist studied in metabolic regulation.

How it is studied

Two incretin receptor pathways influence glucose-dependent insulin secretion, appetite, and gastric emptying.

What the evidence says

Human trials support specific uses of regulated tirzepatide medicines. Evidence belongs to the tested formulation, population, and clinical monitoring; it cannot be transferred automatically to a research reagent.

What remains uncertain

Gastrointestinal effects and other drug-specific risks require clinical assessment. This listing is not an approved medicine or a substitute for a prescription product.

Sources & scope

SURMOUNT-1 randomized obesity trial (2022)

For in-vitro laboratory research only. Not for human or veterinary use.